Glutathione vs SS-31

Overview

Glutathione and SS-31 (elamipretide) both address oxidative stress and cellular protection but through fundamentally different mechanisms. Glutathione is the body’s master endogenous antioxidant, a tripeptide present in virtually all cells. SS-31 is a synthetic mitochondria-targeting tetrapeptide in clinical development that optimizes mitochondrial function at the source of ROS production. They represent conventional antioxidant versus targeted mitochondrial approaches.

Key Facts

Aspect	Glutathione	SS-31 (Elamipretide)
Type	Endogenous tripeptide	Synthetic tetrapeptide
Structure	Glu-Cys-Gly	D-Arg-Dmt-Lys-Phe-NH2
Location	Cytoplasm (primarily)	Mitochondria (concentrated)
Function	ROS scavenging	Mitochondrial optimization
FDA Status	GRAS (supplement)	Investigational drug
Clinical Trials	Limited (IV)	Phase 2/3 ongoing

Mechanism Comparison

Aspect	Glutathione	SS-31
Primary Action	Scavenges existing ROS	Prevents ROS formation
Cellular Location	Cytoplasm, some mito	Mitochondria (1000-5000x)
Target	Free radicals	Cardiolipin
Approach	Cleanup	Prevention

Glutathione Mechanisms

1. Direct Antioxidant

   • Donates electrons to neutralize ROS
   • Reduces hydrogen peroxide
   • Regenerates other antioxidants (C, E)
   • GSH/GSSG redox cycling

2. Detoxification

   • Phase II conjugation reactions
   • Heavy metal binding
   • Xenobiotic metabolism
   • Drug detoxification

3. Cellular Functions

   • Protein thiol protection
   • Immune function support
   • DNA synthesis
   • Cell proliferation regulation

SS-31 Mechanisms

1. Cardiolipin Binding

   • Binds inner mitochondrial membrane
   • Optimizes cytochrome c interaction
   • Stabilizes respiratory complexes
   • Prevents electron leak

2. Mitochondrial Concentration

   • 1000-5000x accumulation
   • Targets source of ROS
   • Not dependent on membrane potential
   • Rapid uptake (minutes)

3. Bioenergetic Improvement

   • Increased ATP/O2 efficiency
   • Reduced ROS production
   • Protected cristae structure
   • Improved respiration

Conceptual Difference

Approach	Glutathione	SS-31
Analogy	Cleaning up spilled water	Fixing the leaky pipe
ROS Strategy	Neutralize after formed	Prevent formation
Location	General cellular	Mitochondria-specific
Efficiency	Stoichiometric	Catalytic-like

Evidence Quality

Factor	Glutathione	SS-31
Basic Science	Extensive	Extensive
Human Trials (therapeutic)	Few	Multiple Phase 2/3
Supplement Studies	Mixed	N/A
IV Studies	Some	Clinical grade
Overall Evidence	Low (as therapy)	Moderate

Glutathione Evidence

Route	Evidence
Oral	Poor absorption, limited efficacy
Liposomal	Improved absorption, limited data
IV	Better delivery, few trials
NAC (precursor)	More clinical evidence

SS-31 Clinical Evidence

Trial	Phase	Outcome
Barth Syndrome	2/3	Positive (67m 6MWT)
MMPOWER-3 (PMM)	3	Primary endpoint not met
PROGRESS-HF	2	Trends toward benefit
ReCLAIM (AMD)	2	Visual improvement

Supplementation vs Drug Development

Aspect	Glutathione	SS-31
Regulatory Path	Supplement	Investigational drug
Standardization	Variable	Pharmaceutical grade
Clinical Trials	Few required	Extensive required
Evidence Standard	Low	High

Glutathione Supplementation Challenges

Issue	Detail
Oral absorption	Poor (digested)
Liposomal claims	Variable, limited data
Blood levels	Difficult to raise orally
Better approach	NAC (precursor) often more effective

SS-31 Drug Development

Factor	Status
Phase 1	Completed
Phase 2	Multiple completed
Phase 3	Ongoing (Barth, AMD)
Safety database	Established

Clinical Applications

Glutathione Uses

Application	Evidence
General wellness	Very low
Skin brightening	Low
Liver support	Low-Moderate
Parkinson’s (IV)	Very low
Detoxification	Theoretical

SS-31 Clinical Targets

Application	Status
Barth Syndrome	Phase 3 (positive)
Primary mitochondrial myopathy	Phase 3 (mixed)
Heart failure	Phase 2 (trends)
Age-related macular degeneration	Phase 2b (ongoing)

Administration

Aspect	Glutathione	SS-31
Routes	Oral, liposomal, IV, inhaled	Subcutaneous, IV
Oral Availability	Poor	Not applicable
Best Delivery	IV or liposomal	Injection

Side Effects

Glutathione

Effect	Notes
Oral	Generally safe
IV	Rare reactions
Skin lightening	Controversial use
Overall	Well-tolerated

SS-31

Effect	Frequency
Injection site	Common
Headache	Occasional
Fatigue	Reported
Generally well-tolerated	Yes

Cost Comparison

Factor	Glutathione	SS-31
Oral Supplement	$20-100/month	N/A
Liposomal	$40-150/month	N/A
IV Therapy	$150-400/session	N/A
Clinical/Research	N/A	Very expensive

Aging and Longevity Context

Glutathione and Aging

Factor	Status
Levels decline with age	Yes
Supplementation reverses	Unclear
Longevity studies	Limited
Best approach	NAC may be better

SS-31 and Aging

Factor	Status
Targets mitochondrial aging	Yes
Mouse studies	Reversed aging markers
Human aging trials	Not specifically conducted
Mechanistic rationale	Strong

Summary

Factor	Glutathione	SS-31
Type	Endogenous antioxidant	Synthetic mito-targeting
Mechanism	Scavenges ROS	Prevents ROS at source
Location	General cellular	Mitochondria-specific
Regulatory Status	Supplement	Investigational drug
Oral Efficacy	Poor	N/A
Clinical Trials	Few	Multiple Phase 2/3
Evidence Level	Moderate (as therapy)	Moderate

Key Takeaways

1. Different approaches: Glutathione scavenges ROS; SS-31 prevents ROS formation
2. Different locations: Glutathione general; SS-31 mitochondria-targeted
3. SS-31 is in clinical trials: Phase 2/3 for real diseases
4. Glutathione oral is limited: Poor absorption reduces efficacy
5. SS-31 is more innovative: Targets source vs cleanup
6. Different regulatory status: Supplement vs investigational drug
7. NAC may be better: For raising glutathione than glutathione itself
8. SS-31 may gain approval: Ongoing trials could lead to FDA approval

---

This comparison is for educational purposes only. Glutathione supplements are widely available but have limited evidence for therapeutic claims. SS-31 is an investigational drug in clinical trials.